Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3076226 in advanced or metastatic cancer
NCT02529553Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2015
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of LY3076226 in cancer and urothelial carcinoma (UC), sponsored by Eli Lilly and Company. Primary endpoint: Maximum Tolerated Dose. Started Sep 2015; status: completed.
02
Drugs
LY3076226
03
Conditions
cancerurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02529553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529553.